Jefferies Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $85

富瑞集團維持布魯克(BRKR.US)買入評級，維持目標價85美元

moomoo資訊 · 2024/11/06 21:31 · 評級/大行評級

Jefferies analyst Tycho Peterson maintains $Bruker Corp (BRKR.US)$ with a buy rating, and maintains the target price at $85.

According to TipRanks data, the analyst has a success rate of 55.4% and a total average return of 7.4% over the past year.

AnalystRecentRatingAutoNews_203162_20241106_27602e158428b5a8c12050b02595a61f43580a7d_1730899835842569_mm_en

Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:

Post the Q3 report, Bruker experienced continued softness in China and within the biopharma sector.
The company encountered a challenging earnings report amidst a difficult macroeconomic climate. Estimates are being adjusted to align with the reduced fiscal 2024 targets; however, the confidence remains that the company is strategically positioned in multi-omics and materials sciences, which should gain from the eventual upturn in biopharmaceutical demand and Chinese market conditions.
Bruker's third-quarter outcomes fell short of expectations, and the company has reduced its organic sales growth forecast for fiscal 2024. This revision was attributed to a sluggish recovery in China and emerging biopharma sectors. The adjustment to the guidance reflects previous projections that were perhaps too optimistic, rather than a significant decline in market conditions during the third quarter. Nevertheless, management has conveyed a confident outlook for 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

富瑞集團分析師Tycho Peterson維持$布魯克 (BRKR.US)$買入評級，維持目標價85美元。

根據TipRanks數據顯示，該分析師近一年總勝率為55.4%，總平均回報率為7.4%。

AnalystRecentRatingAutoNews_203162_20241106_27602e158428b5a8c12050b02595a61f43580a7d_1730899835842569_mm_tc

此外，綜合報道，$布魯克 (BRKR.US)$近期主要分析師觀點如下：

發帖Q3報告，Brucker在中國和生物製藥行業繼續遇到低迷。
公司在一個困難的宏觀經濟環境中遭遇了具有挑戰性的收益報告。預估正在調整以與減少的2024財年目標相一致；然而，信心仍然存在於公司在多組學和材料科學方面的戰略定位，這將受益於生物製藥需求和中國市場狀況最終好轉。
Brucker第三季度業績未達預期，公司已經下調了其2024財年有機銷售增長預測。這一修訂歸因於中國和新興生物製藥板塊復甦乏力。對指導方針的調整反映了之前的預測可能過於樂觀，而不是第三季度市場狀況出現重大下滑。儘管如此，管理層對2025年表達了信心的展望。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Jefferies Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $85

Jefferies Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $85

風險及免責聲明

聲明